Cambridge Heart Hires Adams, Harkness & Hill as Investment Advisors

Business Wire, Sept 12, 2002

Business Editors & Health/Medical Writers

BEDFORD, Mass.--(BUSINESS WIRE)--Sept. 12, 2002

Cambridge Heart, Inc. (NASDAQ:CAMH) today announced that it has engaged the investment banking firm of Adams, Harkness & Hill (AH&H) to advise the Company and its Board of Directors in evaluating various strategic opportunities designed to maximize shareholder value and continue expanding the market penetration of its Microvolt T-Wave Alternans technology for the identification of patients at risk of sudden cardiac death.

David Chazanovitz, President and CEO of Cambridge Heart, Inc. said, "We are very pleased to be working with the highly respected and successful biomedical device and technology banking team from AH&H. They bring a great deal of experience in creatively identifying and evaluating opportunities in the cardiology marketplace, as well as expertise in the funding of medical devices and technologies." Mr. Chazanovitz added, "We intend to evaluate all reasonable alternatives that present the opportunity to accelerate the rollout and utilization of this very important technology."

Jonathan P. Gertler, M.D., Principal, Group Head - Biomedical Devices and Technology for AH&H commented, "The BioMedical Devices and Technology Group at Adams, Harkness & Hill truly is excited to serve as Cambridge Heart's Advisor. Current therapeutic advances for patients with arrhythmic disorders, when combined with recent clinical studies demonstrating the predictive ability of Cambridge Heart's Microvolt T-Wave Alternans test, renders Cambridge Heart's core diagnostic technology of great clinical importance and significant strategic value in the cardiology marketplace."

About Cambridge Heart, Inc.

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1992, is based in Bedford, Massachusetts and is traded on the NASDAQ/NMS under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

About Adams, Harkness & Hill

Adams, Harkness & Hill is a privately held, institutional investment bank focused on emerging growth companies in the technology, healthcare and consumer sectors. With a focus on research-driven investment ideas, Adams, Harkness & Hill offers investment banking, institutional sales and trading, asset management and corporate services. Headquartered in Boston, Massachusetts, and with offices in San Francisco, California, and London, Adams, Harkness & Hill offers the expertise of a national investment bank with the personalized attention and long-term client relationships of a boutique investment bank. European services are offered through Adams, Harkness & Hill, Ltd. More information is available at www.ahh.com. Member NYSE/NASD/SIPC.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.